Minicell display and products therefrom

• US 20040010116A1
• Filed: 05/06/2003
• Published: 01/15/2004
• Est. Priority Date: 05/10/2002
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Ashkar, Samy
• Application Number:
  US10/431,048
• Publication Number:
  US 20040010116A1
• Time in Patent Office: Days
• US Class Current: 530/322
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 5/101 the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• CPC Class Codes: C07K 5/1019 with the first amino acid being basic
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A minicell display method has been developed which has significant advantages for screening peptide libraries for candidates that can bind and effectively modulate a particular biological process. The method, based on the small, anucleate minicell, has increased versatility in generating unique sequences to screen as well as increasing the size of the peptides to be screened. In vivo mutagenesis, at the level of protein synthesis, as well as DNA replication, increases diversification of the library to be screened and therefore substantially increases the number of potential peptides that can modulate a particular biological response or mechanism. A number of representative peptides have been generated using this methodology and demonstrated to have desirable biological and pharmaceutical activities.

Claims

1. An isolated peptide of 100 amino acids or less comprising an amino acid sequence selected from the group consisting of SEQ ID NO:

40, SEQ ID NO;

45, SEQ ID NO;

46, SEQ ID NO;

47, SEQ ID NO;

48, SEQ ID NO;

52, SEQ ID NO;

53, SEQ ID NO;

8, SEQ ID NO;

9, SEQ ID NO;

10, SEQ ID NO;

11, SEQ ID NO;

12, SEQ ID NO;

13, SEQ ID NO;

33, SEQ ID NO;

34, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

39, SEQ ID NO;

41, SEQ ID NO;

42, SEQ ID NO;

49, SEQ ID NO;

50, SEQ ID NO;

51, SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

24, SEQ ID NO;

25, SEQ ID NO;

26, SEQ ID NO;

27, SEQ ID NO;

28, SEQ ID NO;

29, SEQ ID NO;

31, SEQ ID NO;

32, SEQ ID NO;

7, SEQ ID NO;

14, SEQ ID NO;

15, SEQ ID NO;

16, SEQ ID NO;

19, SEQ ID NO;

35, SEQ ID NO;

36, SEQ ID NO;

54, SEQ ID NO;

55, SEQ ID NO;

56, and SEQ ID NO;

57.

2. The peptide of claim 1 wherein the peptide has a modification selected from the group consisting of acylation, methylation, acetylation, phosphorylation, sulfation, prenylation, glycosylation, carboxylation, ubiquitination, amidation, oxidation, hydroxylation, addition of a seleno-group to amino acid side chains, and fluorescent labeling.

3. The peptide of claim 1 further comprising a pharmaceutically acceptable carrier for administration to a patient.

4. The peptide of claim 1 wherein the peptide comprises less than forty amino acids.

5. The peptide of claim 4 wherein the peptide comprises less than twenty amino acids.

6. The peptide of claim 1 wherein the peptide is selected from the group of peptides inhibiting cell/collagen interaction consisting of DDDRKWGFC (SEQ ID NO:

8), DQDQRWGYC (SEQ ID NO;

     9), DRDRAWGYC (SEQ ID NO;

     10), DRQWGLC (SEQ ID NO;

     11), DADQKFGFC (SEQ ID NO;

     12), and ESHQKYGYCGGCDRNNP (SEQ ID NO;

     13).

7. The peptide of claim 1 wherein the peptide is VLEP (SEQ ID NO:

7) and is effective to inhibit macrophage recruitment by molecules selected from the group consisting of osteopontin, C5a and fibronectin.

8. The peptide of claim 1 wherein the peptide inhibits heparin binding and is selected from the group consisting of DSVVYGLRSK (SEQ ID NO:

14) , DSVAYGLKSK (SEQ ID NO;

     15), DSVAYGLKSRSK (SEQ ID NO;

     16), and TPVVPTVDTYDGRGD (SEQ ID NO;

     17).

9. The peptide of claim 1 wherein the peptide is involved in cell attachment or integrin binding, and is selected from the group consisting of TPFIPTESANDGRGDSVAW (SEQ ID NO:

18), CVVVLVL (SEQ ID NO;

     19), LDSAS (SEQ ID NO;

     20), LDSPPAALS (SEQ ID NO;

     21), AADVESPS (SEQ ID NO;

     22), WTGGDDSGSPSSPS (SEQ ID NO;

     23), SDV (SEQ ID NO;

     24), EPEESDVGGAADYP (SEQ ID NO;

     25), QESPSGTDLLVAGSSP (SEQ ID NO;

     26), TPVVPTVDTYDGRGDSLAY (SEQ ID NO;

     27), DKKELAKFQAERSAAS (SEQ ID NO;

     28), DRKEFAKFEEEERARA (SEQ ID NO;

     29), HDRREFAKFQSERSRA (SEQ ID NO;

     30), HDRKEVAKFEAERSKA (SEQ ID NO;

     31), QSWKKQGSPSSPQRRSKGGRKP (SEQ ID NO;

     32), SDQDNNGKGSHES (SEQ ID NO;

     33), and SDQDQDGDGHQDS (SEQ ID NO;

     34).

10. The peptide of claim 1 wherein the peptide binds to fibronectin receptor or induces collagenase and is selected from the group consisting of GRGDNPS (SEQ ID NO:

35), LVPSSKGRGDYLAQSQP (SEQ ID NO;

     36), PNGRGESLAY (SEQ ID NO;

     37), DRYLKFRPV (SEQ ID NO;

     38), HKFVHWKKPVLPSQNNQ (SEQ ID NO;

     39), KGMNYTVR (SEQ ID NO;

     40), DPGYIGSR (SEQ ID NO;

     41), VLPTPTPPGYLSSRSSR (SEQ ID NO;

     42), and KNNQKSEPLIGRKKT (SEQ ID NO;

     43).

11. The peptide of claim 1 wherein the peptide inhibits CD44 interaction with GAG, and includes YYWRQQQYSDPVVSRRRSPS (SEQ ID NO:

44).

12. The peptide of claim 1 wherein the peptide is an anti-angiogenic peptide selected from the group consisting of ATWLPPR (SEQ ID NO:

45), QVGLKPLV (SEQ ID NO;

     46), and TPTVRGAAGSGNQN (SEQ ID NO;

     47).

13. The peptide of claim 1 wherein the peptide inhibits homotypic aggregation of tumor cells and includes HGRFILPWWYAFSPS (SEQ ID NO:

48).

14. The peptide of claim 1 wherein the peptide inhibits cell-cell adhesion and is selected from the group consisting of KKAKKSRRS (SEQ ID NO:

49), KKGKKSKRS (SEQ ID NO;

     50) and RRSRSSTGKKQKSSQSRKTA (SEQ ID NO;

     51).

15. The peptide of claim 1 wherein the peptide is apoptotic to tumor cells and is selected from the group consisting of DGGRGDSLGWYRRGRGGARRSKAKKAAAKNNQKSEPLIGRKKT (SEQ ID NO:

52), KRSR (SEQ ID NO;

     53), acetylated peptide DKMLDP (SEQ ID NO;

     54), and PYAGRGDSVVYGLKKKNNQKAEPLIGRKKTR (SEQ ID NO;

     55).

16. The peptide of claim 2 where the peptide include the acetylated peptide DKMLDP (SEQ ID NO:

54) and specifically targets the invasion complex of metastatic tumor cells.

17. The peptide of claim 1 wherein the peptide includes SEQ ID NO:

54 and inhibits chemotaxis and haptotaxis to OPN, fibronectin, thrombospondin, laminin and chemokines, and inhibits the migration of cells with an assembled invasion complex but has no effect on the migration of eosinophils, neutrophils, epithelial or mesenchymal cells.

18. The peptide of claim 1 wherein the peptide is anti-inflammatory and is selected from the group consisting of SEQ ID NO:

56 and SEQ ID NO;

57.

19. The peptide of claim 2 comprising SEQ ID NO:

55.

20. A minicell expressing the peptide of claim 1.

21. A method of use of the peptide formulation of claim 3 to treat a patient.

22. The method of claim 21, wherein the patient has cancer.

23. The method of claim 21, wherein the patient has an autoimmune disorder.

24. The method of claim 21, wherein the patient has a degenerative disorder.

25. The method of claim 22, wherein the cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, colorectal cancer, hodgkins disease, cancer of the kidney, lung cancer, melanoma, non-hodgkins lymphoma, oral cancer, ovarian cancer, prostate cancer and uterine/cervical cancer.

26. The method of claim 23, wherein the autoimmune disorder is selected from the group consisting of diabetes mellitus, systematic lupus erythematosus (SLE) and rheumatoid arthritis.

27. The method of claim 24, wherein the degenerative disorder is selected from the group consisting of Parkinson'"'"'s disease, Huntington'"'"'s Chorea, Alzheimer'"'"'s disease, and Pick'"'"'s disease.